Artios Pharma raises a $84,000,000 series B round from AbbVie Biotech Ventures, Andera Partners, Arix Bioscience plc, IP Group, M Ventures, Novartis Venture Fund, Pfizer Ventures and SV Health Investors.
September 21, 2016
Artios Pharma raises a $33,200,000 series A round.
Documentaries, videos and podcasts
April 6, 2021
Novartis has struck a deal with Artios Pharma to access DNA damage response (DDR) targets with the potential to enhance its radioligand therapies. Artios, which is run by some of the people behind pioneering DDR drug Lynparza, is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.
February 11, 2021
/PRNewswire/ -- Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the...
December 3, 2020
Germany's Merck is signing up to a small upfront but potentially huge biobucks pact with U.K.-U.S. biotech Artios.